Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 14/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | CD38 | P28907 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967895 | 0.80 | NR3C1 (0.59) | NR3C1KEAP1NFE2L2PGRNR3C2 | |
| SCHEMBL1335286 | 0.78 | KEAP1 (0.67) | NR3C1KEAP1NFE2L2PGRNR3C2 | |
| SCHEMBL3972558 | 0.77 | NR3C1 (0.89) | NR3C1PGRNR3C2AR | |
| SCHEMBL13869170 | 0.74 | KEAP1 (0.65) | NR3C1KEAP1NFE2L2PGRNR3C2 | |
| SCHEMBL20362061 | 0.73 | CA12 (0.50) | CD38TP53GAAMAPTMAPK1 | |
| SCHEMBL29388997 | 0.73 | KEAP1 (0.55) | NR3C1KEAP1NFE2L2PGRNR3C2 | |
| SCHEMBL1291091 | 0.73 | KEAP1 (0.55) | NR3C1KEAP1NFE2L2PGRNR3C2 | |
| SCHEMBL3964987 | 0.73 | NR3C1 (1.00) | NR3C1PGRNR3C2AR | |
| SCHEMBL7156621 | 0.72 | NR3C1 (0.51) | NR3C1KEAP1NFE2L2PGRNR3C2 | |
| SCHEMBL21931626 | 0.70 | KEAP1 (0.59) | NR3C1KEAP1NFE2L2PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363876-B1 | GLUCOCORTICOID RECEPTOR MODULATORS | KAROBIO AB (SE) | 2009-07-29 | — | — | EP | disclosed |
| EP-1363876-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | Abbott Laboratories (US) | 2003-11-26 | — | — | EP | disclosed |
| US-6583180-B2 | Antidiabetic agents | ABBOTT LABORATORIES | 2003-06-24 | — | — | US | disclosed |
| US-20020156311-A1 | Glucocorticoid receptor modulators | KARO BIO AB (SE) | 2002-10-24 | — | — | US | disclosed |
| WO-2002064550-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156311-A1 | Glucocorticoid receptor modulators | NR3C1, NR5A1, NR3C2 | NR3C1 1/4885KEAP1 2044/4885NFE2L2 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.